2017 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
03/20/17Audentes Therapeutics Announces Presentation Of Data From RECENSUS, A Medical Chart Review Of Patients With X-Linked Myotubular Myopathy (XLMTM)
Data confirm and expand understanding of significant medical burden associated with XLMTM SAN FRANCISCO, March 20, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that data from RECENSUS, a medical chart review of patients with X-linked Myotubular Myopathy (XLMTM), will be presented at the 2017 Muscular Dys... 
Printer Friendly Version
03/09/17Audentes Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
- IND for AT132 to treat X-Linked Myotubular Myopathy (XLMTM) submitted - IND for AT342 to treat Crigler-Najjar Syndrome active - Large scale, internal cGMP manufacturing established to support advancement of pipeline programs - Preliminary clinical data from Phase 1 / 2 studies of AT342 and AT132 anticipated in the fourth quarter of 2017 SAN FRANCISCO, March 9, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and com... 
Printer Friendly Version
03/01/17Audentes Therapeutics Announces Commencement of LUSTRO, a Clinical Assessment and Phase 1 / 2 Run-in Study of Patients with Crigler-Najjar Syndrome
- LUSTRO intended to serve as a longitudinal baseline and within-patient control for VALENS, the planned Phase 1 / 2 study of AT342 for the treatment of Crigler-Najjar Syndrome SAN FRANCISCO, March 1, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced the commencement of LUSTRO, a prospective study desig... 
Printer Friendly Version
02/07/17Audentes Therapeutics to Present at Upcoming Investor Conferences
SAN FRANCISCO, Feb. 7, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Matthew R. Patterson, President and Chief Executive Officer, will present at the following upcoming investor conferences: LEERINK Partners 6th Annual Global Healthcare Conference February 15, 2017, 9:00 am ET Lotte New York Palace... 
Printer Friendly Version
02/01/17Audentes Therapeutics Announces FDA Clearance of Investigational New Drug Application for AT342 to Treat Crigler-Najjar Syndrome
Preliminary data from VALENS, the Phase 1 / 2 Clinical Study of AT342, expected by end of 2017 SAN FRANCISCO, Feb. 1, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for AT342, the Company's gen... 
Printer Friendly Version
01/12/17Gene therapy’s big surprise may be in an old South S.F. warehouse
... 
Printer Friendly Version
01/09/17Audentes Therapeutics Provides Full Year 2017 Strategic Outlook and Financial Guidance
- Filed IND with the FDA for AT342 in Crigler-Najjar Syndrome - Large Scale Internal cGMP Manufacturing Capability Expected to be Established for Entire Pipeline of Four Programs - Preliminary Clinical Data from Lead Programs Expected by Year-End SAN FRANCISCO, Jan. 9, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseas... 
Printer Friendly Version
01/04/17Audentes Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO, Jan. 4, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Matthew R. Patterson, President and Chief Executive Officer, will provide a corporate overview and 2017 outlook at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.  The presentation is scheduled for Tuesday, Januar... 
Printer Friendly Version